Wire Stories
InnoCare Releases 2022 Third Quarter Results: Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales
BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2022 third quarter...